BioWorld

April 8, 2002

View Archived Issues

XOMA, Genentech Set Back On Development Of Xanelim

XOMA Ltd.’s stock took a painful hit Friday when the company and its partner, Genentech Inc., released poor preliminary data from a pharmacokinetic study of Xanelim, a psoriasis drug. (BioWorld Today) Read More

Allos Charting Oncology Path, In-Licenses Cancer Product

Read More

Early Days Of Infancy Can Sow Seeds Of Anxiety In Adult Life, If Serotonin In Brain Is Lacking

Read More

Other News To Note

Read More

Appointments And Advancements

Read More